09:44 AM EST, 03/05/2024 (MT Newswires) -- Novo Nordisk ( NVO ) said Tuesday that results from its Flow study showed the trial reached its primary endpoint with a "superior reduction in kidney disease progression, major adverse cardiovascular events and death of 24%" for people that were given semaglutide 1 milligram compared with placebo.

The release of the results comes after the trial was stopped early due to efficacy, a move which was disclosed on Oct. 10, after a recommendation from an Independent Data Monitoring Committee, the company said.

The study compared injectable semaglutide 1 milligram with placebo plus standard of care treatment to prevent the progression of kidney impairment and risk of kidney and cardiovascular deaths in people with type 2 diabetes and chronic kidney disease, Novo Nordisk ( NVO ) said.

The study enrolled 3,533 people with type 2 diabetes and chronic kidney disease, the company said, adding that about 40% of people with type 2 diabetes have chronic kidney disease.

The company said it expects to submit approval requests with regulators for a label expansion for Ozempic in the US and EU this year.

Price: 125.87, Change: -2.08, Percent Change: -1.63